IBC Minutes - September 3rd, 2025
8:30 AM-10:30 AM by Zoom


Glynis Kolling (Chair), called the meeting to order. Members in attendance were Jennifer Kershner (BSO), Aaron Mills (IBC member), Paul Skoglund (IBC member/IBC contact), Matthew Crawford (IBC member), Raphael Malbrue (Animal Containment Expert), Marie Burdick (IBC member), Sam Driver (local non-affiliated member), Tom Leonard (EHS Director), and Ira Schulman (IBC member). Brett Moreau (IBC member) and Stacy Agar (local non-affiliated member) were unable to attend the meeting. The 10 members present exceeded the quorum threshold of seven. Dr. Kolling reminded everybody that anyone who might have a conflict of interest participating in review of a particular protocol should be placed in a breakout room during the discussion of that protocol unless requested to stay and answer questions.

  1. The minutes from the meeting of August 5th, 2025, were approved with no dissent.
  2. The following IARs have no changes from last year or exhibit a minor modification such as stating that they are not using AAV at BSL-1, making room changes, moving inventory to storage only, changing sourcing of materials, small changes to text, or similar changes. All these protocols were approved at either BSL-2 or BSL-3 (when indicated) with no dissent but pending successful laboratory inspection, training, or clerical modifications in indicated cases:
    1. ABEBAYEHU, DANIEL (10756-23) was reviewed by Malbrue and Mills. He studies the crosstalk between immune and stromal cells during fibrosis and tissue regeneration, using viral expression strategies, HDM, and recombinant DNA (III-D-1).
    2. AL-GHADBAN, SARA (12014-24) was reviewed by Leonard and Schulman. She studies inflammatory markers in human adipose tissues using HDM.
    3. BAILEY, STEFANIE (11487-24) was reviewed by Burdick and Mills. She develops and evaluates T-cell immunotherapies using virial expression strategies, HDM, and recombinant DNA (III-D-1). There are training issues to address before approval.
    4. CAI, CHUANXI (9985-22; two CAI protocols in queue this month) was reviewed by Kershner and Crawford. He studies cardiovascular responses to influenza infections using viral expression technology, HDM, and recombinant DNA (III-D-1). There are training issues to address before approval.
    5. CHALFANT, CHARLES (9218-21) was reviewed by Crawford and Kershner. He studies the role of bioactive lipids and RNA splicing in disease states such as cancer, diabetes, inflammation, and infection using viral expression strategies, HDM, and recombinant DNA (III-D-1).
    6. CRISS, ALISON (623-08) was reviewed by Crawford and Leonard. She studies the interaction of pathogens and the immune system, specifically examining interactions between Neisseria gonorrhoeae and neutrophils as well as the cellular activities of anthrax and pertussis toxins, using various BSL-2 agents, biotoxins, HDM, and recombinant DNA (III-D-2).
    7. ENNEN, CHRISTOPHER (10177-22) was reviewed by Malbrue and Burdick. He studies the pathophysiology of adverse pregnancy outcomes using HDM. There are training issues to address before approval.
    8. GRIFFIN, DONALD (5602-17) was reviewed by Crawford and Schulman. He studies the potential role of utilizing biomaterial substrates such as hydrogels in regenerative medicine, using HDM. There are training issues to address before approval.
    9. HEYSELL, SCOTT (6810-19) was reviewed by Mills and Malbrue. He studies human infection with mycobacterium tuberculosis using HDM.
    10. HOFFMAN, PAUL (387-06) was reviewed by Kolling and Schulman. He studies drug resistant pathogens to develop novel therapeutic agents using various BSL2 pathogens and NHPDM.
    11. KAUR, VARINDER (7305-19; HGT) was reviewed by Kolling and Crawford. Her protocol previously contained four HGT clinical trials, but she has stopped all these clinical trials. However, last administration of agent for one trial was in December 2024 and we keep active for a year after last administration of agent.
    12. LOBO, PETER (023-97) was reviewed by Burdick and Leonard. He studies the role of IgM anti-leukocyte autoantibodies in preventing or reducing HIV-1, SIV, and Hepatitis C viral infection of peripheral blood lymphocytes using various BSL-2 agents, biotoxins, and HDM.
    13. MISRA, MADHUSMITA (11453-24) was reviewed by Schulman and Kershner. She studies the clinical impact of regular, repeated, intranasal oxytocin administration to children with autism spectrum disorder on bone density, formation, and resorption, using HDM.
    14. MOHI, GOLAM (5704-17) was reviewed by Crawford and Burdick. He studies hematopoiesis and the molecular pathogenesis of leukemia, using viral expression systems, HDM, and recombinant DNA (III-D-1).
    15. PRICE, RICHARD (407-06) was reviewed by Mills and Malbrue. He studies Parkinson's Disease by developing disease models and then evaluating therapies using viral expression strategies, HDM, and recombinant DNA (III-D-1).
    16. SHIN, JUNG-BUM (744-10) was reviewed by Malbrue and Leonard. He studies sensory hair cells in mice using KO mice, human and monkey cell lines, viral expression strategies, and recombinant DNA (III-D-1).
    17. WANG, YUH-HWA (2937-13) was reviewed by Leonard and Mills. She studies the DNA stability of cloned human fragile site genomic regions, using HDM.
  3. The following IARs have few changes from last year but were discussed in committee:
    1. SHELL, STEVEN (6117-18; WISE) was reviewed by Mills and Kolling. He studies Xeroderma pigmentosum using HDM at UVA Wise. There is a shipping training issues to address before approval.
    2. WORRALL, BRADFORD (1810-11) was reviewed by Kolling and Kershner. He extracts DNA from patient blood and stores in a core facility to use in the future. He needs to define the Other : space that he has listed for his locations after the flooding incident. There are training issues to address and rooms to inspect before approval.
  4. Discussion and review of modified protocols that are not annual renewals- Reviewers can review just the modification or notice other changes as well. Other changes can either be made during that revision cycle or addressed at the subsequent annual review at the reviewee’s discretion. (Note that this type of review leads to approval with no change in annual renewal date.):
    1. CAI, LIHENG (5981-18; MOD) was reviewed by Kolling and Burdick. He studies the effect of soft matrix materials on the responses exhibited by bacterial cells, eukaryotic cells, and tissues, using bacteria and cell lines. He is moving Pseudomonas aeruginosa out of storage only status. His protocol was approvable at BSL2, but there are training issues to address before approval.
  5. Discussion and review of annual renewal protocols that contain modifications:
    1. KUBELICK, KELSEY (11717-14) was reviewed by Kershner and Schulman. She works on developing molecular imaging approaches to target/enhance therapies focused on utilizing ultrasound and photoacoustic imaging techniques and using various BSL-1 and BSL-2 viral expression strategies, HDM, and recombinant DNA (III-D-1; III-E-1). She updated the new AAV at BSL1 questions and added experimental detail concerning a new collaboration. Her protocol was approved at BSL2 with no dissent.
  6. Discussion and review of new protocols:
    1. None at present.
  7. Mid-Month Review- Designated Member and Administrative review:
    1. WALSH, KENNETH (6061-18) Administrative Review. He modified the rooms listings in his protocol. His protocol was approved at BSL-2 after the rooms were approved by the Biosafety office.
  8. Discussion and Review of ACUC protocols with IBC Concerns
    1. AI, HUIWANG (4196; MOD) was reviewed by Crawford and Schulman. He develops novel in vivo imaging tools, both to allow cell tracing and to monitor cell signaling in vertebrates, using viral expressing strategies, HDM, and recombinant DNA (III-D-1). He is adding a new species procedure “Monitoring UDP-Glc levels in mouse liver and muscle”. He needs to either add lentivirus as a biological agent, or else remove mention of lentivirus from the main procedure description.
    2. ANDERSON, KRISTIN (4434; MOD) was reviewed by Mills and Malbrue. She engineers T cells to recognize, attack, and irradicate cancer cells, using viral expression strategies, HDM, and recombinant DNA (III-D-1). She is modifying her routes of administration of biological agents. Her protocol was approved at ABSL2 with no dissent.
    3. DUDLEY, ANDREW (4146; 3rd year) was reviewed by Kershner and Burdick. He studies the role of the tumor microenvironment in regulating tumor progression using BSL2 viral expression systems, HDM, and recombinant DNA (III-D-1). There were no changes in the biological agents section of his protocol. In both species procedures he should remove his listing of lentivirus as a biological agent if it is only used to infect cells in vitro prior to the cells being injected into animals and not directly injected into animals.
    4. GULER, ALI (4191; MOD; BSL1) was reviewed by Kolling and Schulman. He studies the role of discrete cell populations in the CNS in adaptive behavior, using viral expression strategies, HDM, biotoxins, and recombinant DNA (III-D-1; III-E-1). He made text changes affecting AAV at ABSL1 containment information. His protocol was approved at ABSL1 with no dissent.
    5. LINDNER, JONATHAN (4403; 3rd year) was reviewed by Kershner and Kolling. He studies whether lipid-shelled microbubbles can enhance cellular uptake of AAV and studies Von Willebrand factor signaling and platelet adhesion/signaling in pathogenesis using AAV, HDM, and recombinant DNA (III-D-1; III-E-1). He modified his protocol to indicate he will use AAV at both ABSL1 and ABSL2 containment. He needs to need to clarify that his modification of his protocol to declare using AAV at both ABSL1 and ABSL2 in this protocol was intentional, supply a rationale for this change, and identify which AAV constructs will be used at which biocontainment level. Or else pick one level. He also needs to add that any animals injected with AAV at ABSL2 containment will be held at ABSL2 containment for the 72-hour AAV shedding period, if using AAV at ABSL2.
    6. MOHI, GOLAM (4190; MOD) was reviewed by Burdick and Leonard. He studies hematopoiesis and the molecular pathogenesis of leukemia, using viral expression systems, HDM, and recombinant DNA (III-D-1). He is changing injection routes and volumes. His protocol was approved at BSL2 with no dissent.
    7. PEREZ-REYES, EDWARD (4292; 3rd year; BSL1) was reviewed by Leonard and Malbrue. He studies epilepsy using AAV at BSL-1, as well as lentivirus, HDM, and recombinant DNA (III-D-1; III-E-1). There were no changes to the biological agents section of his protocol. His protocol was approved at ABSL1 with no dissent.
    8. PRICE, RICHARD (4406; 3rd year) was reviewed by Mills and Kolling. He studies Parkinson's Disease by developing disease models and then evaluating therapies using viral expression strategies, HDM, and recombinant DNA ((III-D-1). There were no changes in the biological agents section of his protocol. His protocol was approved at ABSL2 with no dissent.
    9. PUROW, BENJAMIN (4404; 3rd year) was reviewed by Crawford and Burdick. He studies the effect of microRNAs and manipulation of DGK alpha or Notch signaling on brain tumors such as gliomas using viral expression strategies, HDM, and recombinant DNA (III-D-1). He removed experiments involving one specific cell line from his protocol. He needs to update the numbering of cell lines he uses in the biological agents section to reflect the removal of one cell line.
    10. TSUNG, ALLAN (4405; 3rd year) was reviewed by Schulman and Leonard. He studies the immune responses in the hepatic immune microenvironment with specific emphasis on the effects of inflammation on hepatic tumor development using viral expression strategies, HDM, biotoxins, and recombinant DNA (III-D-1). He made text changes to his biological agents sections. He needs to clarify whether he is still using human cell lines, or only murine cell lines at present.
    11. ZHANG, HONGJI (4580; NEW) was reviewed by Malbrue and Kershner. He studies the role of preoperative exercise therapy and the effects of inflammation on the liver immune microenvironment in the context of liver ischemia and reperfusion and Metabolic Disfunction -associated Steatohepatitis (MASH) and MASH-associated hepatocellular carcinoma development using viral expression strategies, HDM, biotoxins, and recombinant DNA (III-D-1). This is a new protocol titled “ Immune Responses in Liver Disease and Cancer “. He needs either add use of a BSC in this work, or else to provide a reason why a BSC cannot be used in this work. He also needs to either unclick the AAV use at ABSL1 checkbox, or else describe his work with AAV at ABSL1 in the main procedure description section. This current submission mentions only injection of murine cell lines. Because mouse cell lines do not need to be listed in the biological agent section, he needs to either remove cell lines as a biological agent or to describe his work with human cell lines.
  9. IBC and Biosafety issues:
    1. The IBC discussed a proposed small text change to the ResearchStar system. This change is to strike specific mention of Adenovirus and Murine retroviral vectors from the description of Guideline III-D-1 in the NIH Guidelines. This modification of the ResearchStar system was approved by the IBC with no dissent.
    2. Jenni Kershner, Biosafety officer, let the committee know that the CDC will be on campus on November 12th and 13th for our three-year Select Agent renewal inspection. This is expected to be a hybrid inspection, with some in person and some remote elements. While UVA does not currently have any Select agent work this situation is expected to change once the temporary downrating of high pathogenic influenza virus reverts to Select agent status.
    3. The committee continued its three -year rolling review of UVA IBC policies by reviewing the Biosafety Infraction Policy. This review was tabled until next month to provide adequate time for review.
    4. The committee reviewed an updated autoclave SOP generated by the Biosafety office. This is not an IBC policy, and no revisions were requested.
    5. The committee reviewed an AAV purification document provided by the Dr. Proctor Lab in support of downrating AAV purified in house from BSL2 to BSL1. She recently moved to UVA from Penn state, where she did similar work. It was decided that this document would serve as a useful internal guideline for the IBC vs incorporating this document into an actual IBC policy.
  10. IRE Business:
    1. None at present.
  11. Renewals over 30 days old:
    1. None at present.
  12. Renewals over 60 days old:
    1. None at present.
  13. ACUC protocols for IBC over 30 days old:
    1. None at present.
  14. Renewals over 60 days old:
    1. None at present.
  15. ACUC protocols for IBC over 60 days old:
    1. None at present.
  16. New PIs who are in the process of doing their visits and training:
    1. None at present.